Medpace Holdings, Inc. $MEDP is Giverny Capital Inc.’s 7th Largest Position

Giverny Capital Inc. reduced its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 0.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 253,931 shares of the company’s stock after selling 2,150 shares during the quarter. Medpace comprises 4.6% of Giverny Capital Inc.’s investment portfolio, making the stock its 7th biggest holding. Giverny Capital Inc.’s holdings in Medpace were worth $134,479,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the business. California State Teachers Retirement System boosted its position in shares of Medpace by 53,619.6% during the 2nd quarter. California State Teachers Retirement System now owns 13,989,649 shares of the company’s stock worth $7,408,778,000 after purchasing an additional 13,963,607 shares in the last quarter. BlackRock Inc. purchased a new position in shares of Medpace in the 2nd quarter valued at about $1,323,047,000. AQR Capital Management LLC increased its holdings in shares of Medpace by 65.1% in the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock valued at $518,170,000 after purchasing an additional 404,226 shares in the last quarter. Madison Asset Management LLC purchased a new position in shares of Medpace in the 2nd quarter valued at about $128,956,000. Finally, Bank of America Corp DE acquired a new stake in shares of Medpace in the second quarter valued at about $116,891,000. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Stock Performance

Shares of NASDAQ MEDP opened at $591.29 on Monday. The company’s 50-day moving average price is $574.67 and its 200 day moving average price is $500.02. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $677.90. The stock has a market cap of $16.50 billion, a price-to-earnings ratio of 34.66, a PEG ratio of 2.64 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. During the same quarter in the previous year, the business posted $3.10 earnings per share. The firm’s quarterly revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, research analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Insider Buying and Selling at Medpace

In related news, Director Fred B. Davenport, Jr. sold 7,283 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $606.15, for a total value of $4,414,590.45. Following the sale, the director owned 3,798 shares of the company’s stock, valued at approximately $2,302,157.70. This represents a 65.73% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Susan E. Burwig sold 7,500 shares of the stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $600.00, for a total value of $4,500,000.00. Following the sale, the vice president owned 62,984 shares in the company, valued at approximately $37,790,400. This trade represents a 10.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 134,471 shares of company stock valued at $82,151,311. Company insiders own 20.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on MEDP shares. BMO Capital Markets boosted their price objective on shares of Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a report on Friday, July 24th. Robert W. Baird increased their target price on shares of Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a report on Friday, July 24th. Weiss Ratings upgraded shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 12th. Jefferies Financial Group lowered Medpace from a “buy” rating to a “hold” rating and boosted their price target for the stock from $490.00 to $515.00 in a research note on Tuesday, July 7th. Finally, Mizuho upped their price target on Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Three research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $595.20.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.